Morgan Stanley Remains a Buy on Ascendis Pharma (ASND)
Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ascendis Pharma today and set a price target of $256.00.
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
According to TipRanks, Skor is a 5-star analyst with an average return of 21.1% and a 65.43% success rate. Skor covers the Healthcare sector, focusing on stocks such as Ascendis Pharma, Pharvaris, and Cytokinetics.
In addition to Morgan Stanley, Ascendis Pharma also received a Buy from TipRanks – Google’s Google Biotechnology in a report issued on February 14. However, on the same day, TipRanks – xAI reiterated a Hold rating on Ascendis Pharma (NASDAQ: ASND).
Based on Ascendis Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $245.18 million and a GAAP net loss of $33.25 million. In comparison, last year the company earned a revenue of $173.92 million and had a GAAP net loss of $38.47 million
Read More on ASND:
Disclaimer & DisclosureReport an Issue
- Ascendis Pharma Earnings Call Highlights Growth Momentum
- Ascendis Pharma price target raised to $273 from $240 at Wedbush
- Ascendis Pharma price target raised to $262 from $246 at Oppenheimer
- Ascendis Pharma price target raised to $325 from $256 at Stifel
- Ascendis Pharma price target raised to $256 from $250 at Morgan Stanley
